Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May-Jun;25(3):433-440.
doi: 10.4103/aian.aian_199_22. Epub 2022 Jun 9.

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India

Debashish Chowdhury  1 , Jaydip R Chaudhuri  2 , Pahari Ghosh  3 , Rahul Kulkarni  4 , Sumit Singh  5 , Sneha Thakur  6 , Anup V Thorat  6
Affiliations

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India

Debashish Chowdhury et al. Ann Indian Acad Neurol. 2022 May-Jun.

Abstract

Background: EMPOwER, a 12-week, double-blind (DB), randomized, placebo-controlled study evaluated the efficacy and safety of erenumab in adult patients with episodic migraine (EM) from Asia, the Middle East, and Latin America. This study analyzes the Indian experience for the use of erunumab for prevention of episodic migraine.

Objective: The study aimed to evaluate the efficacy and tolerability of erenumab (70 mg and 140 mg) in EM patients from India.

Methods: Randomized patients received monthly subcutaneous injections of placebo and erenumab 70 mg or 140 mg for 3 months. The primary endpoint was a change from the baseline in monthly migraine days (MMDs) at month 3. Other endpoints included achievement of ≥50%, ≥75%, and 100% reduction in MMD; a change in monthly acute migraine-specific medication treatment days; a change in patient-reported outcomes; and safety assessment.

Results: Of the 539 patients screened, 351 patients were randomized (erenumab, 70 mg: n = 133 and 140 mg: n = 94; placebo: n = 124). The mean (±SD) age, disease duration, and MMD were 35.1 (±8.6) years, 6.77 (±6.01) years, and 7.82 (±2.89) days, respectively. The placebo-adjusted difference in mean MMD for erenumab 70 mg was -0.88 (95% CI, -2.16, 0.39; P = 0.174) days, and that for erenumab 140 mg was -1.01 (-2.42, 0.41; P = 0.164) days versus placebo. Secondary and exploratory endpoints demonstrated consistently better results in both erenumab dosage groups versus placebo. Treatment-emergent adverse events were comparable across groups (erenumab, 70 mg: 22.7% and 140 mg: 24.5%; placebo: 25.2%).

Conclusion: Both doses of erenumab showed numerical improvement for efficacy endpoints and were well-tolerated in the Indian population. No new safety signals were reported.

Keywords: Efficacy; Indian population; erenumab; headache; tolerability episodic migraine.

PubMed Disclaimer

Conflict of interest statement

Debashish Chowdhury, Jaydip Ray Chaudhuri, Pahari Ghosh, Rahul Kulkarni are the principal investigators for Novartis sponsored trials. Sumit Singh has attended advisory boards and is a speaker in Novartis sponsored meetings. Sneha Thakur and Anup Thorat are full time employees of Novartis, India.

Figures

Figure 1
Figure 1
Study design and patient disposition (randomized analysis set)
Figure 2
Figure 2
Change from the baseline in MMD in the Indian sub-population (full analysis set)
See this image and copyright information in PMC

References

    1. Ashina M. Migraine. N Engl J Med. 2020;3839:1866–76. - PubMed
    1. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459–80. - PMC - PubMed
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 19902016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59. - PMC - PubMed
    1. Kulkarni GB, Rao GN, Gururaj G, Stovner LJ, Steiner TJ. Headache disorders and public ill-health in India: Prevalence estimates in Karnataka State. J Headache Pain. 2015;16:67. - PMC - PubMed
    1. Buse DC, Nicholson RA, Araujo AB, Reed ML, Shapiro RE, Ashina S, et al. Migraine care across the healthcare landscape in the United States among those with 4 or greater migraine headache days per month: Results of the OVERCOME study. Headache. 2019;59:16.